Start » About us

About us

The idea

Dermicus teledermatology platform was founded in 2010 by MD, PhD Johan Heilborn.

Dr Heilborn identified from his work as Head of Dermatology at the Karolinska Hospital, Sweden, that he could improve patient care and increase efficiency by using emerging mobile applications and platform to improve the quality and speed of skin cancer diagnosis.

Dr Heilborn also recognised that if such a solution was implemented, with strong training and with continuous learning from the start, clinicians would adopt the new technology. This commitment to easy implementation, training and continuous education remains at the heart of the Dermicus solution today.

We make a difference

Our history

2010

The beginning

Dermicus teledermatology platform was founded in 2010 by MD, PhD Johan Heilborn. Dr Heilborn identified from his work as Head of Dermatology at the Karolinska Hospital, Sweden, that he could improve patient care and increase efficiency by using emerging mobile applications and platform to improve the quality and speed of skin cancer diagnosis. Dr Heilborn also recognised that if such a solution was implemented, with strong training and with continuous learning from the start, clinicians would adopt the new technology. This commitment to easy implementation, training and continuous education remains at the heart of the Dermicus solution today.

2012

Designed with clinicians

The Dermicus platform, mobile application and education program have been developed in close collaboration with Specialists in Dermatology and General Practitioners. Over the years the product development has been advised by legal and technical resources. During 2012 the first beta-version was launched and implemented with Karolinska University Hospital and Primary Care centers in Stockholm, Sweden.

2014

Product launch

In 2014, Dermicus platform and mobile application were CE-certified as a Class I medical device. During the pilot phase, clinical studies had been performed to prove the effectiveness of increasing patient care quality. As a result of the successful pilot and clinical studies, the company Gnosco AB was formed, with serial entrepreneur Daniel Eliasson joining as co-owner and CEO. The focus of Gnosco was to roll-out Dermicus to global healthcare providers and to continue the development to improve patient care quality and support transformational change.

2018

Growth & new markets

The Gnosco team continue to evolve the Dermicus platform and related services with Swedish healthcare customers and clinical users. As of December 2018, the Dermicus platform has delivered more than 15,000 consultations, maintaining more than 60,000 images. Gnosco began expansion into other healthcare markets, with projects in UK.

2020

Large procurement processes

The global effect of Covid-19 increases the pressure on driving efficiency in teledermatology with scale. In Sweden, Gnosco wins Region Skåne and Region Stockholm teledermatology tenders for early diagnosis of skin cancer, for 3.3m patients supported by 390 primary care centres. In the NHS, Dermicus is implemented in all the GP practices of the Isle of Wight NHS Trust for the 144,000 patients, reducing cancer waiting times from 26 days to 0.6 days. Dermicus is shortlisted for the HSJ Awards - Primary Care Innovation of the Year Awards.

2021

Large scale implementation and compliance.

The roll-out of Dermicus in Sweden continues with scale, including the online onboarding of new users across the Regions. In the NHS, the Dermicus Teledermatology platform passes the UK NHSX DTAC assessment and Gnosco achieves international standard of ISO/IEC 27001 Information Security Management certification.

Join us

We are growing and looking for talented people who want to contribute to better healthcare and better outcomes. If you take initiatives and like to work in dynamic and growing companies, please apply.

Jobs